This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van den Bulck, K.
Right arrow Articles by Haesebrouck, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van den Bulck, K.
Right arrow Articles by Haesebrouck, F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2005, p. 2997-3000, Vol. 49, No. 7
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.7.2997-3000.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

In Vitro Antimicrobial Susceptibility Testing of Helicobacter felis, H. bizzozeronii, and H. salomonis

K. Van den Bulck,1* A. Decostere,1 I. Gruntar,2 M. Baele,1 B. Krt,2 R. Ducatelle,1 and F. Haesebrouck1

Department of Pathology, Bacteriology and Poultry Diseases, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium,1 Institute of Microbiology and Parasitology, Faculty of Veterinary Medicine, University of Ljubljana, Ljubljana, Slovenia2

Received 14 December 2004/ Returned for modification 24 January 2005/ Accepted 19 March 2005


arrow
ABSTRACT
 
The susceptibilities of Helicobacter felis (15 strains), H. bizzozeronii (7 strains), and H. salomonis (3 strains) to 10 antimicrobial agents were investigated by determination of the MIC using the agar dilution method. No consistent differences were noticed between the different Helicobacter species, which were all highly susceptible to ampicillin, clarithromycin, tetracycline, tylosin, enrofloxacin, gentamicin, and neomycin, as demonstrated by low MICs. Higher MICs were obtained for lincomycin (up to 8 µg/ml) and spectinomycin (up to 4 µg/ml). Two H. felis strains showed a MIC of 16 µg/ml for metronidazole, suggesting acquired resistance to this antimicrobial agent.


arrow
TEXT
 
"Helicobacter heilmannii," the provisional name of tightly coiled gram-negative bacteria occurring in 0.2 to 2.4% of human gastric biopsy specimens, is associated with various types of gastric pathology (1, 16). Although chronic active gastritis is the predominating pathological profile (6, 16), it appears to a milder degree than gastritis induced by H. pylori, a leading cause of peptic ulcer disease (7, 29). The gastritis may worsen into gastric erosions (6, 30), gastric carcinomas, or mucosa-associated lymphoid tissue lymphomas (9, 23, 28, 29), requiring an effective treatment protocol (21). Commonly a multiple drug regimen is used for H. pylori infections, since single-drug treatment proved to be inefficient (11). Recommended antibiotic agents are clarithromycin and amoxicillin as first-line therapy, and metronidazole together with tetracycline as second-line treatment, both schemes in combination with a gastric-acid-secretion inhibitor (21). Nevertheless, the success rate of these regimens is relatively low, due to the emerging antimicrobial resistance of H. pylori (8, 10). Similar treatment regimens have been used empirically in cases of "H. heilmannii" infections (23), since these bacteria are not culturable in vitro (23, 31), preventing the exploration of their susceptibility pattern. Only once has the in vitro culture of a tightly coiled bacterium from a human stomach, subsequently identified as H. bizzozeronii, been described (2, 18).

Bacteria strongly affiliating with "H. heilmannii," both on a morphological and on a genetic basis, occur in the stomachs of dogs and cats. Hitherto, three different species, H. felis, H. bizzozeronii, and H. salomonis, phenotypically and phylogenetically highly related to one another, have been identified as natural inhabitants of the gastric mucosae of these pet animals (19, 26). Their pathological significance for dogs and cats is still a matter of debate. Antimicrobial treatment of these animals is considered only when helical bacteria are abundant and accompanied by mucosal inflammation and clinical symptoms (26). Veterinarians have to rely on antimicrobials used to eradicate H. pylori (14), as the fastidious nature of H. felis, H. bizzozeronii, and H. salomonis has hitherto impeded the exploration of their antibiotic susceptibility patterns. Recently, these Helicobacter species have been identified in human gastric biopsy specimens histologically found positive for "H. heilmannii," indicating that the latter name comprises an amalgam of different Helicobacter species, at least to some extent originating from dogs and cats (31).

It was the purpose of the present study to investigate the susceptibilities of H. felis, H. bizzozeronii, and H. salomonis to antimicrobial agents commonly used for the treatment of gastritis, in order to improve the management of "H. heilmannii" infections both in humans and in animals.

A total of 15 strains of H. felis, 7 strains of H. bizzozeronii, and 3 strains of H. salomonis, isolated from the gastric mucosae of different cats and dogs and identified by a recently developed multiplex PCR (3), were included in this study (Table 1). The organisms were cultured on brain heart infusion agar (Oxoid, Basingstoke, England) as described previously (3). All incubations occurred at 37°C under microaerobic conditions with 5% oxygen in a closed circuit, created by evacuating 80% of the ambient atmosphere and introducing a gas mixture of 8% CO2, 8% H2, and 84% N2. The isolates were passaged twice to ensure reliable growth and purity.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Canine and feline gastric Helicobacter strains used in this study

Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 29213, and Campylobacter jejuni ATCC 33560, grown on Columbia agar (Oxoid) supplemented with 5% sheep blood, were included as reference strains.

Susceptibility to metronidazole, ampicillin, clarithromycin, lincomycin, tetracycline, tylosin, enrofloxacin, gentamicin, spectinomycin, and neomycin was investigated by the agar dilution method. All antibiotics were supplied by Sigma (St. Louis, MO) as standard powders with known potencies, except for enrofloxacin, purchased from Bayer (Brussels, Belgium). The compounds were dissolved and diluted according to the guidelines of the National Committee for Clinical Laboratory Standards (NCCLS) (25). MIC tests were carried out on Mueller-Hinton II agar (Becton Dickinson, Cockeysville, Md.), supplemented with 10% horse blood. Agar plates contained serial twofold dilutions of the above-stated antibiotics, with final concentrations ranging from 0.03 to 512 µg/ml. Agar plates free of the tested antibiotics were included as controls.

Helicobacter and Campylobacter bacteria grown for 72 h were harvested and suspended in sterile saline to a density of 3 on the McFarland turbidity scale. Suspensions with a density of 0.5 McFarland standard were prepared from overnight-grown reference strains of E. coli and S. aureus. Antibiotic-containing and antibiotic-free plates were seeded by a Steers inoculum replicator (MAST, London, United Kingdom). Plates were read after 1 day for the reference strains and after 4 and 7 days of incubation for both the Helicobacter isolates and the reference strains. The MIC was determined as the lowest concentration of an antimicrobial drug inhibiting visible growth, disregarding a faint haze, of the tested Helicobacter isolates after 7 days of incubation in a microaerophilic atmosphere.

Results for the Helicobacter species are summarized in Table 2. Not all MICs of the antimicrobials tested for the C. jejuni reference strain are included in the NCCLS guidelines. MICs ranged from 0.5 to 1 µg/ml for metronidazole, from 0.5 to 2 µg/ml for clarithromycin, from 1 to 4 µg/ml for spectinomycin, from 4 to 8 µg/ml for ampicillin, and from 4 to 32 µg/ml for lincomycin. The MICs determined for tylosin and neomycin were 16 and 1 µg/ml, respectively.


View this table:
[in this window]
[in a new window]
  		TABLE 2. Distribution of MICs for 15 H. felis, 7 H. bizzozeronii, and 3 H. salomonis strains of animal origin

The fastidious and slow-growing nature of these bacteria led us to incubate the plates longer than 72 h, which is the time recommended by the NCCLS for susceptibility testing of H. pylori (25). In a first stage, the incubation period was extended to 4 days. Growth was definable only for a minority of the isolates after this time, and a 7-day incubation period revealed no different outcome of these MICs. This prolongation markedly facilitated determination of the MIC due to a more pronounced growth of the Helicobacter isolates. After incubation for 7 days, the MICs of the reference strains for all antimicrobial agents tested were 1 to 2 log2 dilutions higher than the MICs recorded after 1 day of incubation, but still in the range premised by the NCCLS (24).

In general, the MICs did not show consistent differences between the different Helicobacter species. All isolates seemed to be highly susceptible to ampicillin, clarithromycin, enrofloxacin, gentamicin, tetracycline, tylosin, and neomycin, as low MIC levels were noted. The MICs of clarithromycin, amoxicillin, and tetracycline are completely in line with those indicating susceptibility in H. pylori (10). MICs of lincomycin, metronidazole, and spectinomycin were markedly higher. For metronidazole, a broad MIC range was noticed.

Selection of antimicrobial agents was based on their common application for H. pylori eradication in humans and/or for treatment of gastrointestinal disease in companion animal medicine. The latter justifies the inclusion of lincomycin, tylosin, spectinomycin, gentamicin, and neomycin in the study protocol next to ampicillin, clarithromycin, metronidazole, and tetracycline. Enrofloxacin is fairly frequently used in small-animal veterinary medicine for the treatment of infections with principally gram-negative bacteria. Ciprofloxacin, the primary active metabolite of enrofloxacin, expressing an antimicrobial activity similar to that of enrofloxacin (32), is considered an important alternative for H. pylori eradication in cases of metronidazole and/or clarithromycin resistance (4, 27).

Currently, no standard methods are described for MIC determination for non-H. pylori Helicobacter species. The NCCLS proposes the agar dilution method using Mueller-Hinton agar supplemented with sheep blood as the method of choice for Campylobacter jejuni and related species (24) and for H. pylori (25). In the present study, however, horse blood was chosen, because it is known to support excellent growth of the organisms of interest and its supplementation is advised by the NCCLS for testing fastidious organisms. A typical feature of H. felis, H. bizzozeronii, and H. salomonis is the need for fresh, moist agar plates, on which viable bacterial cells grow as a spreading film (13, 17). This growth characteristic was thought to impede agar dilution testing, leading to the assumption that animal models would be the only way to assess antimicrobial drug susceptibility, a method which has already been applied to test H. felis (5). In the present study, all isolates except H. bizzozeronii strains M20 and M25 consistently grew well on dry plates as single colonies. The explanation for the poor growth of these particular strains may be found in the lack of specificity of the McFarland standard, which is an indication of the amount of cellular material rather than of the quantity of viable bacteria (15). The same phenomenon has already been noted for H. pylori (15).

Up to now, the only antimicrobial agent for which the NCCLS guidelines have established a breakpoint in the case of H. pylori susceptibility testing is clarithromycin. H. pylori is considered resistant when the MIC is ≥1 µg/ml (25). Other breakpoints to define the resistance level of H. pylori have only been suggested in the scientific literature for metronidazole (≥8 µg/ml), tetracycline (≥2 µg/ml), and ampicillin (≥8 µg/ml) (20, 22). Upon extrapolation of these breakpoints to H. felis, H. bizzozeronii, and H. salomonis, acquired resistance to metronidazole was observed for one H. bizzozeronii isolate (MIC, 8 µg/ml) and two H. felis isolates (MIC, 16 µg/ml). All three H. salomonis isolates in the present study were susceptible to metronidazole, although resistance to this agent has already been reported in the past (17). These observations urge new investigations on the mechanism responsible for metronidazole resistance in non-H. pylori Helicobacter species. The mechanism in H. pylori is based on nonsense mutations in the rdxA gene, a gene coding for an oxygen-insensitive NADPH nitroreductase, which enables the reduction of metronidazole into its active component hydroxylamine (12). The genetic alterations generate a premature stop in the translated protein, thereby inactivating the nitroreductase and the antimicrobial activity of metronidazole.

Whether our findings suggest the possibility of efficiently applying these antimicrobials in monotherapy for eradication of non-H. pylori Helicobacter spp. is questionable. Experimental studies with mice intragastrically infected with H. felis proved monotherapy of metronidazole, erythromycin, tetracycline, or amoxicillin all ineffective for eradication of these spirally shaped organisms (5). With respect to the possible discrepancy between in vitro and in vivo studies, one may refer to the behavior of H. pylori, which is highly susceptible to antimicrobials in vitro while its eradication in patients requires aggressive triple or quadruple therapy (8, 11).

The present study is the first to investigate the normal in vitro susceptibilities of H. felis, H. bizzozeronii, and H. salomonis to several antimicrobials, notwithstanding their fastidious nature and the lack of standardized guidelines on MIC testing for these Helicobacter species.


arrow
ACKNOWLEDGMENTS
 
This work was supported by the Research Fund of Ghent University, Ghent, Belgium, Codenr. GOA12050602.

We thank Richard L. Ferrero for providing H. felis strains CS5, CS6, and DS1. The excellent technical assistance provided by Jurgen De Craene is greatly appreciated.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Pathology, Bacteriology and Poultry Diseases, Ghent University, Faculty of Veterinary Medicine, Salisburylaan 133, B-9820 Merelbeke, Belgium. Phone: 32 (0)9 264 74 36. Fax: 32 (0)9 264 74 94. E-mail: kathleen.vandenbulck{at}UGent.be. Back


arrow
REFERENCES
 
    1
  1. Andersen, L. P. 2001. New Helicobacter species in humans. Dig. Dis. 19:112-115.[CrossRef][Medline]
    2. 2
  2. Andersen, L. P., A. Norgaard, S. Holck, J. Blom, and L. Elsborg. 1996. Isolation of a "Helicobacter heilmannii"-like organism from the human stomach. Eur. J. Clin. Microbiol. Infect. Dis. 15:95-96.[CrossRef][Medline]
    3. 3
  3. Baele, M., K. Van den Bulck, A. Decostere, P. Vandamme, M. L. Hanninen, R. Ducatelle, and F. Haesebrouck. 2004. Multiplex PCR assay for differentiation of Helicobacter felis, H. bizzozeronii, and H. salomonis. J. Clin. Microbiol. 42:1115-1122.[Abstract/Free Full Text]
    4. 4
  4. Cammarota, G., R. Cianci, O. Cannizzaro, L. Cuoco, G. Pirozzi, A. Gasbarrini, A. Armuzzi, M. A. Zocco, L. Santarelli, F. Arancio, and G. Gasbarrini. 2000. Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection. Aliment. Pharmacol. Ther. 14:1339-1343.[CrossRef][Medline]
    5. 5
  5. Dick-Hegedus, E., and A. Lee. 1991. Use of a mouse model to examine anti-Helicobacter pylori agents. Scand. J. Gastroenterol. 26:909-915.[Medline]
    6. 6
  6. Dieterich, C., P. Wiesel, R. Neiger, A. Blum, and I. Corthésy-Theulaz. 1998. Presence of multiple "Helicobacter heilmannii" strains in an individual suffering from ulcers and in his two cats. J. Clin. Microbiol. 36:1366-1370.[Abstract/Free Full Text]
    7. 7
  7. Dunn, B. E., H. Cohen, and M. J. Blaser. 1997. Helicobacter pylori. Clin. Microbiol. Rev. 10:720-741.[Abstract]
    8. 8
  8. Ecclissato, C., M. A. Marchioretto, S. Mendonca, A. P. Godoy, R. A. Gersoni, M. Deguer, H. Piovesan, J. G. Ferraz, and J. Pedrazzoli. 2002. Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication. Helicobacter 7:53-59.[Medline]
    9. 9
  9. Forman, D., D. G. Newell, F. Fullerton, J. W. Yarnell, A. R. Stacey, N. Wald, and F. Sitas. 1991. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ 302:1302-1305.
    10. 10
  10. Glupczynski, Y. 1998. Antimicrobial resistance in Helicobacter pylori: a global overview. Acta Gastroenterol. Belg. 61:357-366.[Medline]
    11. 11
  11. Glupczynski, Y., A. Burette, J. F. Nyst, C. De Prez, E. De Koster, and M. Deltenre. 1988. Campylobacter pylori-associated gastritis: attempts to eradicate the bacteria by various antibiotics and anti-ulcer regimens. Acta Gastroenterol. Belg. 51:329-337.[Medline]
    12. 12
  12. Goodwin, A., D. Kersulyte, G. Sisson, S. J. O. Veldhuyzen van Zanten, D. E. Berg, and P. S. Hoffman. 1998. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase. Mol. Microbiol. 28:383-393.[CrossRef][Medline]
    13. 13
  13. Hänninen, M. L., I. Happonen, S. Saari, and K. Jalava. 1996. Culture and characteristics of Helicobacter bizzozeronii, a new canine gastric Helicobacter sp. Int. J. Syst. Bacteriol. 46:160-166.[Abstract/Free Full Text]
    14. 14
  14. Happonen, I., J. Linden, and E. Westermarck. 2000. Effect of triple therapy on eradication of canine gastric helicobacters and gastric disease. J. Small Anim. Pract. 41:1-6.[Medline]
    15. 15
  15. Hartzen, S. H., L. P. Andersen, A. Bremmelgaard, H. Colding, M. Arpi, J. Kristiansen, T. Justesen, F. Espersen, N. Frimodt-Moller, and O. Bonnevie. 1997. Antimicrobial susceptibility testing of 230 Helicobacter pylori strains: importance of medium, inoculum, and incubation time. Antimicrob. Agents Chemother. 41:2634-2639.[Abstract]
    16. 16
  16. Heilmann, K. L., and F. Borchard. 1991. Gastritis due to spiral shaped bacteria other than Helicobacter pylori: clinical, histological and ultrastructural findings. Gut 32:137-140.[Abstract/Free Full Text]
    17. 17
  17. Jalava, K., M. Kaartinen, M. Utriainen, I. Happonen, and M. L. Hänninen. 1997. Helicobacter salomonis sp. nov., a canine gastric Helicobacter sp. related to Helicobacter felis and Helicobacter bizzozeronii. Int. J. Syst. Bacteriol. 47:975-982.[Abstract/Free Full Text]
    18. 18
  18. Jalava, K., S. L. On, C. S. Harrington, L. P. Andersen, M. L. Hänninen, and P. A. Vandamme. 2001. A cultured strain of "Helicobacter heilmannii," a human gastric pathogen, identified as H. bizzozeronii: evidence for zoonotic potential of Helicobacter. Emerg. Infect. Dis. 7:1036-1038.[Medline]
    19. 19
  19. Jalava, K., S. L. On, P. A. Vandamme, I. Happonen, A. Sukura, and M. L. Hänninen. 1998. Isolation and identification of Helicobacter spp. from canine and feline gastric mucosa. Appl. Environ. Microbiol. 64:3998-4006.[Abstract/Free Full Text]
    20. 20
  20. Loo, V. G., C. A. Fallone, E. De Souza, J. Lavallee, and A. N. Barkun. 1997. In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole. J. Antimicrob. Chemother. 40:881-883.[Abstract/Free Full Text]
    21. 21
  21. Malfertheiner, P., F. Megraud, C. O'Morain, A. P. Hungin, R. Jones, A. Axon, D. Y. Graham, G. Tytgat, et al. 2002. Current concepts in the management of Helicobacter pylori infection—the Maastricht 2-2000 Consensus Report. Aliment. Pharmacol. Ther. 16:167-180.[Medline]
    22. 22
  22. Mendonca, S., C. Ecclissato, M. S. Sartori, A. P. Godoy, R. A. Guerzoni, M. Degger, and J. Pedrazzoli, Jr. 2000. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter 5:79-83.[CrossRef][Medline]
    23. 23
  23. Morgner, A., N. Lehn, L. P. Andersen, C. Thiede, M. Bennedsen, K. Trebesius, B. Neubauer, A. Neubauer, M. Stolte, and E. Bayerdörffer. 2000. ‘Helicobacter heilmannii’-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 118:821-828.[CrossRef][Medline]
    24. 24
  24. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. Approved standard—2nd ed. M31-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    25. 25
  25. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing; 12th informational supplement. M100-S12. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    26. 26
  26. Neiger, R., and K. W. Simpson. 2000. Helicobacter infection in dogs and cats: facts and fiction. J. Vet. Intern. Med. 14:125-133.[CrossRef][Medline]
    27. 27
  27. Sanchez, J. E., N. G. Saenz, M. R. Rincon, I. T. Martin, E. G. Sanchez, and M. J. Martinez. 2000. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J. Antimicrob. Chemother. 46:283-285.[Abstract/Free Full Text]
    28. 28
  28. Stolte, M., E. Bayerdörffer, A. Morgner, B. Alpen, T. Wündisch, C. Thiede, and A. Neubauer. 2002. Helicobacter and gastric MALT lymphoma. Gut 50(Suppl. 3):III19-24.
    29. 29
  29. Stolte, M., G. Kroher, A. Meining, A. Morgner, E. Bayerdorffer, and B. Bethke. 1997. A comparison of Helicobacter pylori and H. heilmannii gastritis. A matched control study involving 404 patients. Scand. J. Gastroenterol. 32:28-33.[Medline]
    30. 30
  30. Sykora, J., V. Hejda, J. Varvarovska, F. Stozicky, F. Gottrand, and K. Siala. 2003. ‘Helicobacter heilmannii ’ related gastric ulcer in childhood. J. Pediatr. Gastroenterol. Nutr. 36:410-413.[CrossRef][Medline]
    31. 31
  31. Van den Bulck, K., A. Decostere, M. Baele, A. Driessen, J. C. Debongnie, A. Burette, M. Stolte, R. Ducatelle, and F. Haesebrouck. 2005. Identification of non-Helicobacter pylori spiral organisms in gastric samples from humans, dogs, and cats. J. Clin. Microbiol. 43:2256-2260.[Abstract/Free Full Text]
    32. 32
  32. Varma, R., A. H. Ahmad, L. D. Sharma, P. Aggarwal, and V. Ahuja. 2003. Pharmacokinetics of enrofloxacin and its active metabolite ciprofloxacin in cows following single dose intravenous administration. J. Vet. Pharmacol. Ther. 26:303-305.[Medline]

Antimicrobial Agents and Chemotherapy, July 2005, p. 2997-3000, Vol. 49, No. 7
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.7.2997-3000.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Van den Bulck, K., Decostere, A., Baele, M., Vandamme, P., Mast, J., Ducatelle, R., Haesebrouck, F. (2006). Helicobacter cynogastricus sp. nov., isolated from the canine gastric mucosa.. Int. J. Syst. Evol. Microbiol. 56: 1559-1564 [Abstract] [Full Text]  
  • Fritz, E. L., Slavik, T., Delport, W., Olivier, B., van der Merwe, S. W. (2006). Incidence of Helicobacter felis and the Effect of Coinfection with Helicobacter pylori on the Gastric Mucosa in the African Population.. J. Clin. Microbiol. 44: 1692-1696 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van den Bulck, K.
Right arrow Articles by Haesebrouck, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van den Bulck, K.
Right arrow Articles by Haesebrouck, F.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»